WinSanTor, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.winsantor.com
Clinical Trials
4
Active:1
Completed:3
Trial Phases
1 Phases
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (100.0%)A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
Phase 2
Active, not recruiting
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Drug: PlaceboDrug: WST-057 Active
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- WinSanTor, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05488873
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- WinSanTor, Inc
- Target Recruit Count
- 16
- Registration Number
- NCT05005078
- Locations
- 🇺🇸
Palmtree Clinical Research, Palm Springs, California, United States
🇺🇸University of California San Diego, San Diego, California, United States
A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
Phase 2
Completed
- Conditions
- Diabetes MellitusPainful Diabetic Neuropathy
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- WinSanTor, Inc
- Target Recruit Count
- 58
- Registration Number
- NCT04786340
- Locations
- 🇺🇸
Eastern Virginia Medical School, Norfolk, Virginia, United States
A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy
Phase 2
Completed
- Conditions
- Peripheral NeuropathyPainful Diabetic NeuropathyDiabetic Neuropathies, Painful
- Interventions
- Drug: Placebo High DoseDrug: WST-057 (4% pirenzepine) High Dose 4mLDrug: WST-057 (4% pirenzepine) Lose Dose 2mLDrug: Placebo Low Dose
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- WinSanTor, Inc
- Target Recruit Count
- 58
- Registration Number
- NCT04005287
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦McMaster University Medical Centre, Hamilton, Ontario, Canada
🇨🇦Ottawa Hospital Research Institute Civic Campus, Ottawa, Ontario, Canada
News
No news found